1 Title

- 2 The Causal Association between Gut Microbiota and Pancreatic Cancer: A Two-sample
- 3 Mendelian Randomization Analysis in European and East Asian Populations

4 Authors

- 5 Yinbo Xiao^{1#}, Xiang Li^{2#}, Long Zou¹, Daniel M. Wall², Zhiyong Liang¹
- ¹Department of Pathology, State Key Laboratory of Complex Severe and Rare Diseases,
- 7 Molecular Pathology Research Centre, Peking Union Medical College Hospital, Chinese
- 8 Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- 9 ²School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, Sir
- 10 Graeme Davies Building, University of Glasgow, Glasgow G12 8TA, United Kingdom
- 11 # These authors contributed to the work equally.
- 12 **Corresponding author**: Zhiyong Liang (e-mail: liangzy@pumch.cn)
- 13
- 14 Financial support: This study was supported by funding from National Natural Science
- 15 Foundation of China (No. 82072749).
- 16 Author contributions: Yinbo Xiao and Xiang Li: conception and design of the study and
- 17 original draft preparation. Long Zou: literature search and original draft preparation. Zhiyong
- 18 Liang and Daniel M. Wall: revision and approval of the manuscript. All authors approved the
- 19 final version of the article.
- 20 Declaration of conflict of interest: The authors declare that they have no conflicts of
- 21 interest.
- 22 Ethics statement: Ethical review and approval were not required for this study because this
- 23 study was based on public databases.

24 Abstract

- 25 Background and Aim: Alterations in the gut microbiota strongly correlate with the onset of
- pancreatic cancer (PC). However, any causal relationship between gut microbiota alterations
 and PC risk remains unknown.
- 28 *Methods*: We comprehensively investigated PC-related microorganisms in European and East
- 29 Asian populations through the application of Mendelian randomization (MR). The PC
- 30 genome-wide association study (GWAS) databases for European and East Asian individuals
- 31 were acquired from the UK and Japanese Biobanks, respectively. Primary analytical
- 32 methods, including the inverse variance weighted (IVW) method, weighted median,
- 33 Maximum likelihood method and MR PRESSO, were employed to estimate the potential
- 34 causal association between gut microbiota and PC. Additionally, we performed sensitivity
- 35 analysis and reverse MR analysis.
- 36 *Results*: By IVW method, overall 17 bacterial taxa were identified with potential causal
- 37 correlations to PC. The PC-associated gut microbiota signatures varied across different
- 38 populations. Among these, 4 specific taxa exhibited potential causality with PC, with
- 39 statistical significance in all four MR methods. Specifically, the *Alcaligenaceae* family was
- 40 identified as protective, while genus *Sutterella*, order *Bacilliales* and genus *Enterohabdus*
- 41 were associated with increased risk of PC. Among the European population within the UK
- 42 biobank, the Alcaligenaceae family, genus Sutterella, and order Bacillales were connected to
- 43 PC, while genus *Enterohabdus* was linked to PC in the Japanese cohort.
- 44 *Conclusion*: Our study implicates certain members of the gut microbiota in PC onset based
- 45 on genetics. Further investigations of the gut-pancreas axis may lead to the development of
- 46 novel microbiome targeted prevention strategies for PC.

47 Keywords

- 48 pancreatic cancer, gut microbiota, Mendelian randomization analysis.
- 49

50 Introduction

51 Pancreatic cancer (PC), especially pancreatic ductal adenocarcinoma, is one of the most 52 lethal malignancies worldwide [1]. With an estimated 49,830 deaths attributed to PC in 2022, it remains the fourth most common cause of cancer-related deaths in the US [2]. 53 54 Moreover, it is predicted to become the second leading cause of cancer-related deaths by 55 2030 in the US [3]. The incidence and mortality rates of PC are continuously increasing year 56 by year, unfortunately with minimal progress in the overall survival rate [4]. Thus, it is urgent 57 to gain a deeper understanding of the biological mechanisms underlying PC carcinogenesis, 58 potentially leading to novel treatment and management strategies for PC to reduce such 59 public health burden.

60 The role of the gut microbiome in PC development, known as the microbiome-pancreas axis, has gained significant attention [5]. Microbiota from the gut can enter the pancreas via the 61 62 circulatory system or pancreatic duct [6, 7]. Numerous research studies have revealed that 63 gut microbiota alterations are involved in the advent of PC [8-11], even though the 64 underlying molecular mechanisms remain unclear. Moreover, some epidemiological studies have demonstrated that the risk of PC is positively correlated to the abundance of some gut 65 66 microbiota, such as Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and 67 Helicobacter Pylori [10, 12, 13]. These studies indicated that the gut microbiota could serve 68 as biomarkers for PC in clinical practice and be utilized for early detection of PC and 69 prognosis of outcomes. However, a causal role for the gut microbiota in PC has not been 70 established, due to confounding factors and the potential for reverse causality [14-16]. 71 Mendelian randomization (MR) is an epidemiological method whereby genetic variants are 72 employed as instrumental variables (IVs) to determine the causal relationship between risk 73 factors and disease outcomes [17, 18]. The use of genetic variants is advantageous as they 74 are randomly distributed during conception, reducing the impacts of confounding factors 75 and eliminating reverse causation bias. Consequently, MR analysis is less susceptible to the 76 influence of environmental and self-adopted confounding factors [19]. In this study, MR 77 offers a valuable approach to estimate the causal link between the gut microbiota and the 78 risk of PC. 79

Using MR analysis, previous studies have identified the causal relationships between the gut
microbiome and several cancers, including liver cancer [20], colorectal cancer [21], and lung
cancer [22]. However, any causal association between the gut microbiota and PC is still

- 82 unclear. Furthermore, most MR studies are largely derived from European populations,
- 83 while there is a limited number of studies employing MR analysis in non-European cohorts.
- 84 Here, we performed a two-sample MR analysis to evaluate the association between the gut
- 85 microbiome and PC risk among both European and East Asian populations. Our study can
- 86 enhance the theoretical basis for the gut-pancreas axis leading to novel insights into the
- 87 predictors of PC as well as potential treatment targets.

88 Methods

89 Exposure data

- 90 Genetic variants related to the gut microbiota composition were acquired from the large-
- scale genome-wide association study (GWAS) [23]. The gut microbiota was profiled by
- 92 targeting three variable regions V1–V2, V3–V4 and V4 of the 16S rRNA gene. The meta-
- analysis encompassed a total of 18,340 participants derived from 24 cohorts originating
- 94 from several countries including the United States, Canada, Israel, South Korea, Germany,
- 95 the United Kingdom. Following adjustment for age, gender, technical covariates, and genetic
- 96 principal components, the quantitative microbiome trait loci analysis yielded a total of 211
- 97 GWAS summary statistics associated with microbial taxa. These were 9 phyla, 16 classes, 20
- 98 orders, 35 families (including 3 families with unknown classification), and 131 genera (with
- 99 12 genera of unknown classification). The summary data is available for download from
- 100 <u>https://mibiogen.gcc.rug.nl/</u>.

101 Outcome data

- 102 The UK Biobank and the Japan Biobank were used to investigate the causal relationship
- 103 between the microbiome and pancreatic cancer. The cohort data from the UK Biobank of PC
- 104 involved 589 PC cases and 393372 healthy control. Summary analysis statistics are available
- 105 from the Lee Lab (<u>https://www.leelabsg.org/resources</u>). The summary GWAS data of the
- 106 Japan Biobank included 442 PC cases and 195745 healthy controls. Data was acquired from
- 107 the IEU Open GWAS project (<u>https://gwas.mrcieu.ac.uk/datasets/</u>).

108 Assumptions

- 109 The schematic representation of the investigation is depicted in **Figure 1**. In this study, the
- 110 gut microbiota was considered as the exposure, while PC was regarded as the outcome.
- 111 Three fundamental assumptions were necessary for a proper MR study. First, the genetic
- 112 variants designated as IVs were strongly related to the exposure. Second, the relationships

113 between genetic variations and outcomes were not influenced by any other confounding

114 variables. Third, it should be noted that the impact of genetic variations on the outcome was

only mediated by their influence on the specific exposure under investigation. It meant that

116 no occurrence of horizontal pleiotropy was shown between the genetic variants and the

117 outcome.

118 Instrumental variable selection

119 Excluding 15 unknown classifications, a total of 196 taxa at five different levels (phylum, 120 class, order, family, and genera) were conducted as the exposure datasets. Potential IVs were 121 selected by single nucleotide polymorphisms (SNPs) with a less stringent significant 122 association at a threshold of $P < 1.0 \times 10^{-5}$. The approach was employed to augment the 123 pool of SNPs accessible for conducting sensitivity tests, as demonstrated in prior studies [23, 124 24]. Independent SNPs were clumped as IVs based on linkage disequilibrium (LD) $R^2 < 0.01$ 125 and clumping distance equal to 10,000 kb. The strengths of the IVs were estimated by F 126 statistics. Specifically, the extent to which the IVs accounted for variance was computed for 127 each exposure. F statistics were calculated with the following equation, $r^2 * (N - 1 - k) / [(1 - k) - 1 - k]]]$ 128 r²)* k], where r² was the variance explained, N was the sample size and k was the number of 129 IVs [25]. To calculate F statistics for independent IVs, k was equal to 1. Finally, independent 130 IVs with F-statistics below 10 were deemed to be weak IVs and therefore were eliminated 131 from the analysis. To identify whether selective IVs were associated with confounders, PhenoScanner was applied to exclude IVs significantly associated ($P < 5 \times 10^{-8}$) with potential 132

133 confounders (i.e., obesity, smoking, diet, or other diseases).

134 Mendelian randomization analysis

MR analysis was conducted in R using TwoSampleMR package version 0.5.7 [26]. Selected 135 136 IVs from different gut microbiota taxa were combined with the PC outcome SNPs dataset. To 137 ensure the effects of SNPs on the exposure corresponding to the same allele as the effects on the outcome, shared SNPs were harmonised across exposure and outcome databases. At 138 139 least 3 shared SNPs available between exposure and outcome were then selected for further 140 MR analysis. To evaluate causal estimates between the gut microbiota and the risk of PC, MR 141 causality tests were performed using four different approaches: inverse-variance-weighted 142 (IVW) method, weighted median, maximum-likelihood method and MR-PRESSO [27]. In 143 particular, the IV method of estimation was fundamentally a meta-analysis technique which 144 was operated under the assumption that IVs had a causal impact on the outcome solely

through the exposure, rather than through any other pathways [28]. The weighted median

estimator provided valid estimations of causal effect when no more than 50% of the

147 information was from invalid instruments. MR PRESSO was employed to estimate the

148 pleiotropy, which corrected the estimation by eliminating outliers from the IVW model.

149 Therefore, the presence of a causal relationship was determined when a statistically

significant *P* value (P < 0.05) was obtained from any of the four methods used in the MR

151 analysis.

152 Sensitivity analysis

153 After MR analysis, sensitivity analysis was performed to evaluate potential heterogeneity 154 and pleiotropy. The Cochran's Q statistics were employed for heterogeneity analysis. When 155 the p-value of Q statistics was less than 0.05, it might be interpreted as evidence of 156 heterogeneity. MR-Egger intercept, as well as MR-PRESSO test, were conducted to monitor 157 the potential horizontal pleiotropy. An insignificant P value (P > 0.05) in the MR-Egger 158 intercept test was defined as the absence of pleiotropy. The MR-PRESSO test was also 159 conducted to examine pleiotropic biases and address the pleiotropic effects by eliminating 160 outliers. MR analysis report was not supported by the MR PRESSO outliers-adjusted test 161 (P > 0.05) representing substantial pleiotropy. In addition, leave-one-out analysis was 162 performed to determine if the causal estimates were biased by any one single SNP. Leave-163 one-out analysis was able to identify one SNP driving the signal when all, but one leave-oneout configuration had P < 0.05. 164

165 Reverse MR analysis

To determine whether PC had any causal impact on the identified significant microbiota, a reverse MR analysis was conducted (PC as the exposure and the identified significant gut microbiota as the outcome), by using SNPs that were strongly associated with PC as IVs (p < 5x10⁻⁶). Causal tests based on the MR framework were then conducted, following the same methodology as described in the section "Mendelian randomization analysis". To eliminate intricate causality possibility, we also excluded any results in which the *P*-value of reverse MR was less than 0.05.

173 Results

174 Selection of instrumental variables

175 IVs were sorted by $p < 1x10^{-6}$. After excluding unknown bacterial genera or ones containing

176 less than three IVs, a total of 119 bacterial genera were used as exposure datasets. The F-

177 statistics of IVs were more than 10, suggesting that there was no evidence of weak

- 178 instrument bias. Details about the selected IVs for 119 genera were shown in
- 179 Supplementary Table S1.

180 Association of specific members of the gut microbiota with PC

- 181 In the MR analysis, 17 bacterial genera were genetically predicted associated with the risk of
- 182 PC in the IVW method_of MR analysis. Specifically, there were 11 genera (class *Bacyeroidia*,
- 183 family Alcaligenaceae, family Veillonellacease, genus Bilophila, genus Eggerthella, genus
- 184 *LachnospiraceaeUCG004*, genus *LachnospiraceaeUCG010*, genus *Parasutterella*, genus
- 185 *Sutterella*, order *Bacillales*, and order *Bacteroidales*) in European ancestry from the UK

186 Biobank (**Table 1**), while 6 genera (class *Atinobacteria*, family *Christensenellaceae*, genus

- 187 Ruminococcusgnavus group, genus Enterohabdus, genus Ruminococcus1, order
- 188 *Burkholderiales*) were identified in East Asian ancestry from the Japan Biobank (**Table 2**). The
- scatter plots of IV potential effects on PC versus gut microbiota in the European and East
- Asian populations were demonstrated in **Supplementary Figure S1 and S2**, respectively. In
- 191 order to identify the strongest evidence of significant risk factors between any microbial taxa
- and PC, 17 significant bacterial genera were valued in 4 different MR analysis methods (IVW,
- 193 weighted median, Maximum likelihood, and MR PRESSO). The most significant risk factors
- 194 were required to achieve a *p*-value below 0.05 in all four distinct techniques of MR analysis.
- 195 Hence, four microbial taxa were identified that fulfilled these requirements, including three
- 196 taxa (family *Alcaligenaceae*, genus *Sutterella*, and order *Bacillales*) being associated with PC
- 197 in the UK Biobank cohort, and one taxon (genus *Enterohabdus*) being associated with PC in
- 198 Japan Biobank cohort (as shown in **Table 1** and **2**). Meanwhile, the IVW, weighted median,
- 199 Maximum likelihood, and MR PRESSO, all 4 analysis methods produced similar casual
- 200 estimates for magnitude and direction. In detail, the family Alcaligenaceae (OR = 0.5, 95% CI
- 201 = 0.29-0.86, p = 0.011, IVW) had a protective effect on PC in European populations, while
- 202 genus Sutterella (OR = 2.25, 95% CI = 1.27-3.99, p = 0.005, IVW) and order Bacillales (OR =
- 203 1.60, 95% CI = 1.18-2.16, *p* = 0.002, IVW) were associated with a higher risk of PC. The
- 204 findings from the Japanese cohort indicated a heightened likelihood of developing PC

205 correlated with the presence of the genus *Enterohabdus* (OR = 2.38, 95% CI = 1.40-4.04, *p* =
206 0.001, IVW).

207 Sensitivity Analyses

208 The Cochran's Q statistics for all 17 significant risk factors of gut microbiota in PC showed no 209 significant heterogeneity (p > 0.05) (**Supplementary Table S2**). Meanwhile, no evidence of 210 horizontal pleiotropy for gut microbiota in PC with p > 0.05 was demonstrated by the MR-211 Egger regression intercept approach (Supplementary Table S3). The heterogeneity of 17 212 significant risk factors of PC was also revealed by the MR-PRESSO global test, and the 213 analysis revealed no outliers in the results (Supplementary Table S4). Moreover, leave-one-214 out analysis exhibited no significant difference in causal estimations of all 17 bacterial 215 genera on PC (Supplementary Figure S3 and S4). No association between Pancreatic cancer 216 and the following taxonomic groups was observed in the reverse MR analysis of the UK 217 Biobank data: class Bacyeroidia, family Alcaligenaceae, family Veillonellacease, genus 218 *Bilophila*, genus *Eggerthella*, genus *LachnospiraceaeUCG004*, genus 219 LachnospiraceaeUCG010, genus Parasutterella, guens Sutterella, order Bacillales, and order 220 Bacteroidales (Table 3). As there were few IVs identified from the Japanese Biobank, only 7 221 IVs were selected even when the cut-off *p*-value was set as 1×10^{-5} . Therefore, we could not 222 perform reserve MR analysis between PC and the gut microbiome in the population from Eastern Asia. Detailed information on the IVs (P value < 5x10⁻⁶) used in the reverse MR 223

analyses was shown in **Supplementary Table S5**.

225 Discussion

226 Our study used MR analysis to offer valuable insights into the potential causal relationship

- 227 between gut microbiota and PC. IVW estimates suggested that within the European
- 228 population, class Bacteroidia, family Alcaligenaceae, genus Eggerthella, genus
- 229 LachnospiraceaeUCG004, genus Parasutterella, order Bacteroidales were related to the
- 230 reduced risk of PC, while family *Veillonellaceae*, genus *Bilophila*, genus *Lanchnospiraceae*
- 231 UCG010, genus Sutterella, and order Bacillales were positively related to the risk of PC. In
- the East Asian population, several gut microbiota members were identified to be related to
- the reduced risk of PC, including family *Christensenellaceae*, genus *Ruminococcusgnavus*
- 234 group, genus Ruminococcus 1, and order Burkholderiales, while the level of class
- 235 Actinobacteria and genus Enterorhabdus were positively related to the PC. These findings

not only contribute to the advancement of our knowledge of microbiota in the developmentof cancer, but also highlight the importance of ethnicity in the risk of PC.

238 Based on the PC GWAS database from the UK biobank and the Japan biobank, our study 239 indicated that the PC-associated gut microbiome displayed widespread regional differences. 240 Furthermore, a recent meta-analysis conducted on the Finnish biobank data identified a 241 distinct group of bacteria associated with PC. However, these findings varied from the results 242 obtained from biobanks in the UK and Japan. [29, 30]. All this evidence suggested that the PC-related gut microbiota signatures varied across different populations. Previous studies 243 244 demonstrated strong associations between race (European, African, Asian) and different 245 genera abundances in most cancer types [31]. The incidence of PC is greater in Europe than 246 in East Asia [32]. The disparity may be associated with gut microbiome differences. However, 247 the microbiome profiles among various racial groups in PC, are not well understood. The 248 different abundant bacteria might be attributed to various dietary patterns among 249 individuals from distinct regions. It is noteworthy that the diversity in human gut 250 microbiome composition between ethnic groups manifests as early as three months after 251 birth [33]. Hence, diverse geographic populations should be considered in the microbiota-252 based disease models [34]. The identification of unique gut microbiota linked to PC in the UK 253 and Japan provide an opportunity to further conduct country-specific studies on the 254 development of PC.

255 The findings generated from our MR analysis were consistent with the previously published 256 results obtained from 16s rRNA sequencing of microbiota in PC patients. The clinical PC 257 faecal microbial profile by 16s rRNA sequencing reported that Eggerthella and Parasutterella 258 were significantly decreased in PC patients compared with healthy control [35]. Another 259 faecal microbiome signature in PC patients was characterised by a decreased presence of 260 bacterial families commonly in the healthy gut, namely *Ruminococcaceae* and 261 Lachnospiraceae; and an increased presence of Veillonellaceae [36]. Additionally, a 262 comparison of the relative abundances of each microbial species revealed that Sutterella Wadsworthensis and Bilophila were significantly enriched, while Bacteroildes Rodentium was 263 significantly decreased in PC as compared with healthy controls [37, 38]. Thus, the two-264 265 sample Mendelian randomization study is thought to provide a convincing approach for 266 evaluating the relationships between gut microbiota and PC, as it is compatible with faecal 267 16s sequencing results.

268 According to our findings, a decrease in the abundance of *Lachnospiraceae* and 269 *Ruminococcaceae*, as well as an increase in *Veillonellaceae*, were associated with the PC risk. 270 Strikingly, a similar profile of altered gut microbiota was also exhibited in the patients 271 diagnosed with cirrhosis [39, 40]. In a linkage study in southern England, elevated risks of PC 272 were identified to be related to earlier liver diseases, such as alcoholic cirrhosis, primary 273 biliary cirrhosis and unspecified cirrhosis [41]. Combined with our results, new research will 274 be proposed that a potential role of altered gut flora in cirrhosis patients could contribute to 275 the increased susceptibility to PC. Besides, it is well acknowledged that obesity substantially 276 elevates the risk of PC; however, the underlying mechanisms connecting the two remain 277 poorly understood [42]. The genus Eggerthella, as a protective factor for PC, exhibited a 278 significantly lower abundance in obese individuals compared to non-obese ones [43]. 279 Conversely, the genus *Sutterella* as a risk factor for PC, exhibited an increase in obese people 280 [44, 45]. Given the similarity of the microbiota profiles between the obese population and 281 PC patients, it is reasonable to assume that the microbiota alteration, such as the metabolic 282 changes linked to the *Eggerthella* and *Sutterella* [46], could mediate the mechanism by 283 which the obesity initiates the development of PC. Taken together, our study can provide 284 novel insights into the relationships between PC, the microbiome and other risk factors, 285 which could enhance our knowledge of PC development.

286 The therapeutic techniques aiming at the cancer-associated microbiome have been 287 conducted in clinical trials. In this context, our study found that Ruminococcus and 288 Lachnospiraceae were severed as the protective role of PC, suggesting novel and potential 289 treatment targets for gut microbiome-based therapy. Hester et al. [47] demonstrated that 290 the consumption of a substantial quantity of dietary fibre led to the production of a 291 significant level of butyrate production by several bacterial family, such as Lachnospiraceae 292 and *Ruminococcaceae*, which had preventive properties against the development of colon 293 cancer. The utilization of probiotics in healthy individuals has been found to inhibit the 294 development of colon carcinoma by increasing the number of *Ruminococcus* species and 295 *Clostridiales* bacteria [48, 49]. Therefore, the use of probiotics containing *Ruminococcus* 296 could have promise as a novel therapeutic approach for mitigating the onset of PC. On the 297 other hand, based on our findings, other PC-associated microbiota are worthy of further 298 investigation, making this a promising direction for targeted gut microbiome-based therapy 299 for PC.

- 300 Our study has several limitations. First, our research included a total of 119 microbial taxa;
- 301 however, we did not investigate potential causal associations at the species level. Second,
- 302 MR analysis is a computer-based correlation analysis between gut microbiota and PC,
- 303 without explaining the underlying process. It would be advantageous to validate the
- 304 outcomes via functional experiments. Third, the present study included people of European
- and East Asian descent, perhaps restricting the generalizability of the findings to other
- 306 populations.
- 307 In conclusion, this study identified several candidate bacteria that have potential association
- 308 with PC. Variations in the PC-associated gut microbiota signatures are evidenced with
- 309 geographical location, which may explain the disparity of PC incidence across nations. The
- 310 identification of PC-associated gut microbiota provides the foundation for the exploration of
- 311 novel microbiota-targeted therapy for PC. Further studies are needed to better characterise
- the potential role of these gut microbiota in the pathogenic mechanisms of PC.

313 Reference

- Siegel, R.L., K.D. Miller, and A. Jemal, *Cancer statistics, 2020.* CA Cancer J Clin, 2020.
 70(1): p. 7-30.
- Siegel, R.L., K.D. Miller, H.E. Fuchs, and A. Jemal, *Cancer statistics, 2022.* CA Cancer J
 Clin, 2022. **72**(1): p. 7-33.
- Huang, B.Z., L. Liu, J. Zhang, U.S.C.P.R. Team, S.J. Pandol, S.R. Grossman, and V.W.
 Setiawan, *Rising Incidence and Racial Disparities of Early-Onset Pancreatic Cancer in the United States, 1995-2018.* Gastroenterology, 2022. **163**(1): p. 310-312 e1.
- Khalaf, N., H.B. El-Serag, H.R. Abrams, and A.P. Thrift, *Burden of Pancreatic Cancer: From Epidemiology to Practice*. Clin Gastroenterol Hepatol, 2021. **19**(5): p. 876-884.
- Thomas, R.M. and C. Jobin, *Microbiota in pancreatic health and disease: the next frontier in microbiome research.* Nat Rev Gastroenterol Hepatol, 2020. 17(1): p. 5364.
- Fritz, S., T. Hackert, W. Hartwig, F. Rossmanith, O. Strobel, L. Schneider, K. Will Schweiger, M. Kommerell, M.W. Buchler, and J. Werner, *Bacterial translocation and infected pancreatic necrosis in acute necrotizing pancreatitis derives from small bowel rather than from colon.* Am J Surg, 2010. 200(1): p. 111-7.
- Pushalkar, S., M. Hundeyin, D. Daley, C.P. Zambirinis, E. Kurz, A. Mishra, N. Mohan, B.
 Aykut, M. Usyk, L.E. Torres, G. Werba, K. Zhang, Y. Guo, Q. Li, N. Akkad, S. Lall, B.
 Wadowski, J. Gutierrez, J.A. Kochen Rossi, J.W. Herzog, B. Diskin, A. Torres-
- Hernandez, J. Leinwand, W. Wang, P.S. Taunk, S. Savadkar, M. Janal, A. Saxena, X. Li,
 D. Cohen, R.B. Sartor, D. Saxena, and G. Miller, *The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression*.
 Cancer Discov, 2018. 8(4): p. 403-416.
- Aykut, B., S. Pushalkar, R. Chen, Q. Li, R. Abengozar, J.I. Kim, S.A. Shadaloey, D. Wu, P.
 Preiss, N. Verma, Y. Guo, A. Saxena, M. Vardhan, B. Diskin, W. Wang, J. Leinwand, E.

- Kurz, J.A. Kochen Rossi, M. Hundeyin, C. Zambrinis, X. Li, D. Saxena, and G. Miller, *The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL*. Nature,
 2019. **574**(7777): p. 264-267.
- Wei, M.Y., S. Shi, C. Liang, Q.C. Meng, J. Hua, Y.Y. Zhang, J. Liu, B. Zhang, J. Xu, and X.J.
 Yu, *The microbiota and microbiome in pancreatic cancer: more influential than expected.* Mol Cancer, 2019. **18**(1): p. 97.
- Fan, X., A.V. Alekseyenko, J. Wu, B.A. Peters, E.J. Jacobs, S.M. Gapstur, M.P. Purdue,
 C.C. Abnet, R. Stolzenberg-Solomon, G. Miller, J. Ravel, R.B. Hayes, and J. Ahn, *Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study.* Gut, 2018. 67(1): p. 120-127.
- Sethi, V., S. Kurtom, M. Tarique, S. Lavania, Z. Malchiodi, L. Hellmund, L. Zhang, U.
 Sharma, B. Giri, B. Garg, A. Ferrantella, S.M. Vickers, S. Banerjee, R. Dawra, S. Roy, S.
 Ramakrishnan, A. Saluja, and V. Dudeja, *Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response.* Gastroenterology, 2018. **155**(1): p. 33-37 e6.
- Lee, A.A., Q.L. Wang, J. Kim, A. Babic, X. Zhang, K. Perez, K. Ng, J. Nowak, N. Rifai,
 H.D. Sesso, J.E. Buring, G.L. Anderson, J. Wactawski-Wende, R. Wallace, J.E. Manson,
 E.L. Giovannucci, M.J. Stampfer, P. Kraft, C.S. Fuchs, C. Yuan, and B.M. Wolpin,
 Helicobacter pylori Seropositivity, ABO Blood Type, and Pancreatic Cancer Risk From 5 Prospective Cohorts. Clin Transl Gastroenterol, 2023. 14(5): p. e00573.
- Yuan, M., Y. Xu, and Z. Guo, Association of oral microbiome and pancreatic cancer: a
 systematic review and meta-analysis. Therap Adv Gastroenterol, 2022. 15: p.
 17562848221123980.
- 361 14. Fewell, Z., G. Davey Smith, and J.A. Sterne, *The impact of residual and unmeasured*362 *confounding in epidemiologic studies: a simulation study.* Am J Epidemiol, 2007.
 363 166(6): p. 646-55.
- 36415.Smith, G.D. and A.N. Phillips, Confounding in epidemiological studies: why365"independent" effects may not be all they seem. BMJ, 1992. **305**(6856): p. 757-9.
- Phillips, A.N. and G.D. Smith, *How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely.* J Clin
 Epidemiol, 1991. 44(11): p. 1223-31.
- 369 17. Richmond, R.C. and G. Davey Smith, *Mendelian Randomization: Concepts and Scope.*370 Cold Spring Harb Perspect Med, 2022. **12**(1).
- Yarmolinsky, J., K.H. Wade, R.C. Richmond, R.J. Langdon, C.J. Bull, K.M. Tilling, C.L.
 Relton, S.J. Lewis, G. Davey Smith, and R.M. Martin, *Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?* Cancer Epidemiol
 Biomarkers Prev, 2018. 27(9): p. 995-1010.
- Burgess, S. and S.G. Thompson, *Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects.* Am J Epidemiol, 2015. **181**(4):
 p. 251-60.
- Ma, J., J. Li, C. Jin, J. Yang, C. Zheng, K. Chen, Y. Xie, Y. Yang, Z. Bo, J. Wang, Q. Su, J.
 Wang, G. Chen, and Y. Wang, Association of gut microbiome and primary liver cancer: *A two-sample Mendelian randomization and case-control study.* Liver Int, 2023. **43**(1): p. 221-233.
- Ni, J.J., X.S. Li, H. Zhang, Q. Xu, X.T. Wei, G.J. Feng, M. Zhao, Z.J. Zhang, L. Zhang, G.H.
 Shen, and B. Li, *Mendelian randomization study of causal link from gut microbiota to colorectal cancer*. BMC Cancer, 2022. 22(1): p. 1371.

385 22. Zhou, H., J. Liu, J. Shen, W. Fang, and L. Zhang, Gut Microbiota and Lung Cancer: A 386 Mendelian Randomization Study. JTO Clin Res Rep, 2020. 1(3): p. 100042. 387 23. Kurilshikov, A., C. Medina-Gomez, R. Bacigalupe, D. Radjabzadeh, J. Wang, A. 388 Demirkan, C.I. Le Roy, J.A. Raygoza Garay, C.T. Finnicum, X. Liu, D.V. Zhernakova, M.J. 389 Bonder, T.H. Hansen, F. Frost, M.C. Ruhlemann, W. Turpin, J.Y. Moon, H.N. Kim, K. Lull, 390 E. Barkan, S.A. Shah, M. Fornage, J. Szopinska-Tokov, Z.D. Wallen, D. Borisevich, L. 391 Agreus, A. Andreasson, C. Bang, L. Bedrani, J.T. Bell, H. Bisgaard, M. Boehnke, D.I. 392 Boomsma, R.D. Burk, A. Claringbould, K. Croitoru, G.E. Davies, C.M. van Duijn, L. 393 Duijts, G. Falony, J. Fu, A. van der Graaf, T. Hansen, G. Homuth, D.A. Hughes, R.G. 394 Ijzerman, M.A. Jackson, V.W.V. Jaddoe, M. Joossens, T. Jorgensen, D. Keszthelyi, R. 395 Knight, M. Laakso, M. Laudes, L.J. Launer, W. Lieb, A.J. Lusis, A.A.M. Masclee, H.A. 396 Moll, Z. Mujagic, Q. Qibin, D. Rothschild, H. Shin, S.J. Sorensen, C.J. Steves, J. Thorsen, 397 N.J. Timpson, R.Y. Tito, S. Vieira-Silva, U. Volker, H. Volzke, U. Vosa, K.H. Wade, S. 398 Walter, K. Watanabe, S. Weiss, F.U. Weiss, O. Weissbrod, H.J. Westra, G. Willemsen, 399 H. Payami, D. Jonkers, A. Arias Vasquez, E.J.C. de Geus, K.A. Meyer, J. Stokholm, E. 400 Segal, E. Org, C. Wijmenga, H.L. Kim, R.C. Kaplan, T.D. Spector, A.G. Uitterlinden, F. 401 Rivadeneira, A. Franke, M.M. Lerch, L. Franke, S. Sanna, M. D'Amato, O. Pedersen, 402 A.D. Paterson, R. Kraaij, J. Raes and A. Zhernakova, Large-scale association analyses 403 identify host factors influencing human gut microbiome composition. Nat Genet, 404 2021. 53(2): p. 156-165. 405 24. Sanna, S., N.R. van Zuydam, A. Mahajan, A. Kurilshikov, A. Vich Vila, U. Vosa, Z. 406 Mujagic, A.A.M. Masclee, D. Jonkers, M. Oosting, L.A.B. Joosten, M.G. Netea, L. 407 Franke, A. Zhernakova, J. Fu, C. Wijmenga, and M.I. McCarthy, Causal relationships 408 among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat 409 Genet, 2019. 51(4): p. 600-605. 410 25. Burgess, S., A. Butterworth, and S.G. Thompson, Mendelian randomization analysis 411 with multiple genetic variants using summarized data. Genet Epidemiol, 2013. 37(7): 412 p. 658-65. 413 26. Hemani, G., J. Zheng, B. Elsworth, K.H. Wade, V. Haberland, D. Baird, C. Laurin, S. 414 Burgess, J. Bowden, R. Langdon, V.Y. Tan, J. Yarmolinsky, H.A. Shihab, N.J. Timpson, 415 D.M. Evans, C. Relton, R.M. Martin, G. Davey Smith, T.R. Gaunt, and P.C. Haycock, The 416 MR-Base platform supports systematic causal inference across the human phenome. 417 Elife, 2018. 7. 418 27. Verbanck, M., C.Y. Chen, B. Neale, and R. Do, Detection of widespread horizontal 419 pleiotropy in causal relationships inferred from Mendelian randomization between 420 *complex traits and diseases.* Nat Genet, 2018. **50**(5): p. 693-698. 421 28. Bowden, J., M.F. Del Greco, C. Minelli, G. Davey Smith, N. Sheehan, and J. Thompson, 422 A framework for the investigation of pleiotropy in two-sample summary data 423 Mendelian randomization. Stat Med, 2017. 36(11): p. 1783-1802. 424 29. Jiang, Z., Y. Mou, H. Wang, L. Li, T. Jin, H. Wang, M. Liu, and W. Jin, Causal effect 425 between gut microbiota and pancreatic cancer: a two-sample Mendelian 426 randomization study. BMC Cancer, 2023. 23(1): p. 1091. 427 30. Zhu, S.J. and Z. Ding, Association between gut microbiota and seven gastrointestinal 428 diseases: A Mendelian randomized study. J Gene Med, 2023: p. e3623. 429 Luo, M., Y. Liu, L.C. Hermida, E.M. Gertz, Z. Zhang, Q. Li, L. Diao, E. Ruppin, and L. 31. 430 Han, Race is a key determinant of the human intratumor microbiome. Cancer Cell, 431 2022. **40**(9): p. 901-902.

- 432 32. Collaborators, G.B.D.P.C., *The global, regional, and national burden of pancreatic*433 *cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a*434 *systematic analysis for the Global Burden of Disease Study 2017.* Lancet
 435 Gastroenterol Hepatol, 2019. 4(12): p. 934-947.
- Mallott, E.K., A.R. Sitarik, L.D. Leve, C. Cioffi, C.A. Camargo, Jr., K. Hasegawa, and S.R.
 Bordenstein, *Human microbiome variation associated with race and ethnicity emerges as early as 3 months of age.* PLoS Biol, 2023. 21(8): p. e3002230.
- 439 34. He, Y., W. Wu, H.M. Zheng, P. Li, D. McDonald, H.F. Sheng, M.X. Chen, Z.H. Chen, G.Y.
 440 Ji, Z.D. Zheng, P. Mujagond, X.J. Chen, Z.H. Rong, P. Chen, L.Y. Lyu, X. Wang, C.B. Wu,
 441 N. Yu, Y.J. Xu, J. Yin, J. Raes, R. Knight, W.J. Ma, and H.W. Zhou, *Regional variation*442 *limits applications of healthy gut microbiome reference ranges and disease models.*443 Nat Med, 2018. 24(10): p. 1532-1535.
- Ren, Z., J. Jiang, H. Xie, A. Li, H. Lu, S. Xu, L. Zhou, H. Zhang, G. Cui, X. Chen, Y. Liu, L.
 Wu, N. Qin, R. Sun, W. Wang, L. Li, W. Wang, and S. Zheng, *Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China.* Oncotarget,
 2017. 8(56): p. 95176-95191.
- Half, E., N. Keren, L. Reshef, T. Dorfman, I. Lachter, Y. Kluger, N. Reshef, H. Knobler, Y.
 Maor, A. Stein, F.M. Konikoff, and U. Gophna, *Fecal microbiome signatures of pancreatic cancer patients.* Sci Rep, 2019. **9**(1): p. 16801.
- 37. Nagata, N., S. Nishijima, Y. Kojima, Y. Hisada, K. Imbe, T. Miyoshi-Akiyama, W. Suda,
 M. Kimura, R. Aoki, K. Sekine, M. Ohsugi, K. Miki, T. Osawa, K. Ueki, S. Oka, M.
 Mizokami, E. Kartal, T.S.B. Schmidt, E. Molina-Montes, L. Estudillo, N. Malats, J.
 Trebicka, S. Kersting, M. Langheinrich, P. Bork, N. Uemura, T. Itoi, and T. Kawai,
 Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer
- 456 From a Multinational Study. Gastroenterology, 2022. **163**(1): p. 222-238.
- Matsukawa, H., N. Iida, K. Kitamura, T. Terashima, J. Seishima, I. Makino, T. Kannon, K.
 Hosomichi, T. Yamashita, Y. Sakai, M. Honda, T. Yamashita, E. Mizukoshi, and S.
 Kaneko, *Dysbiotic gut microbiota in pancreatic cancer patients form correlation networks with the oral microbiota and prognostic factors.* Am J Cancer Res, 2021.
 11(6): p. 3163-3175.
- 462 39. Chen, Y., F. Yang, H. Lu, B. Wang, Y. Chen, D. Lei, Y. Wang, B. Zhu, and L. Li,
 463 *Characterization of fecal microbial communities in patients with liver cirrhosis.*464 Hepatology, 2011. 54(2): p. 562-72.
- 40. Bajaj, J.S., P.B. Hylemon, J.M. Ridlon, D.M. Heuman, K. Daita, M.B. White, P.
 466 Monteith, N.A. Noble, M. Sikaroodi, and P.M. Gillevet, *Colonic mucosal microbiome*467 *differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to*468 *cognition and inflammation*. Am J Physiol Gastrointest Liver Physiol, 2012. **303**(6): p.
 469 G675-85.
- 470 41. Goldacre, M.J., C.J. Wotton, D. Yeates, V. Seagroatt, and J. Collier, *Liver cirrhosis, other*471 *liver diseases, pancreatitis and subsequent cancer: record linkage study.* Eur J
 472 Gastroenterol Hepatol, 2008. 20(5): p. 384-92.
- 473 42. Li, Z., L. Jin, L. Xia, X. Li, Y. Guan, and H. He, Body mass index, C-reactive protein, and
 474 pancreatic cancer: A Mendelian randomization analysis to investigate causal
 475 pathways. Front Oncol, 2023. 13: p. 1042567.
- 476 43. Verdam, F.J., S. Fuentes, C. de Jonge, E.G. Zoetendal, R. Erbil, J.W. Greve, W.A.
 477 Buurman, W.M. de Vos, and S.S. Rensen, *Human intestinal microbiota composition is*

- 478 associated with local and systemic inflammation in obesity. Obesity (Silver Spring),
 479 2013. 21(12): p. E607-15.
- 480 44. Oduaran, O.H., F.B. Tamburini, V. Sahibdeen, R. Brewster, F.X. Gomez-Olive, K. Kahn,
 481 S.A. Norris, S.M. Tollman, R. Twine, A.N. Wade, R.G. Wagner, Z. Lombard, A.S. Bhatt,
 482 and S. Hazelhurst, *Gut microbiome profiling of a rural and urban South African cohort*483 *reveals biomarkers of a population in lifestyle transition.* BMC Microbiol, 2020. 20(1):
 484 p. 330.
- 485 45. Gao, X., M. Zhang, J. Xue, J. Huang, R. Zhuang, X. Zhou, H. Zhang, Q. Fu, and Y. Hao,
 486 Body Mass Index Differences in the Gut Microbiota Are Gender Specific. Front
 487 Microbiol, 2018. 9: p. 1250.
- 488 46. de Wit, D.F., N.M.J. Hanssen, K. Wortelboer, H. Herrema, E. Rampanelli, and M.
 489 Nieuwdorp, *Evidence for the contribution of the gut microbiome to obesity and its*490 *reversal.* Sci Transl Med, 2023. **15**(723): p. eadg2773.
- 491 47. Hester, C.M., V.R. Jala, M.G. Langille, S. Umar, K.A. Greiner, and B. Haribabu, *Fecal*492 *microbes, short chain fatty acids, and colorectal cancer across racial/ethnic groups.*493 World J Gastroenterol, 2015. 21(9): p. 2759-69.
- 494 48. Walia, S., R. Kamal, S.S. Kanwar, and D.K. Dhawan, *Cyclooxygenase as a target in*495 *chemoprevention by probiotics during 1,2-dimethylhydrazine induced colon*496 *carcinogenesis in rats.* Nutr Cancer, 2015. **67**(4): p. 603-11.
- 497 49. Zhang, X., Y. Zhao, J. Xu, Z. Xue, M. Zhang, X. Pang, X. Zhang, and L. Zhao, *Modulation*498 of gut microbiota by berberine and metformin during the treatment of high-fat diet499 induced obesity in rats. Sci Rep, 2015. 5: p. 14405.

- ____

517 Figure 1

518 The study design and the overall workflow.

Assumption 1: the genetic variant is directly associated with the exposure; Assumption 2: the genetic variant is not related to factors known to obscure the connection between the exposure and the effect; Assumption 3: the genetic variant has no effect other than through the exposure.



Table 1

546 Causal associations of the gut microbiota with pancreatic cancer risk in the European

547 population.

Exposure	Method		p value	OR(95%CI)
class.Bacteroidia.id.912	Inverse variance weighted	- -	0.040	0.52 (0.28, 0.97)
class.Bacteroidia.id.912	Weighted median		0.213	0.61 (0.28, 1.33)
class.Bacteroidia.id.912	Maximum likelihood		0.031	0.53 (0.30, 0.95)
class.Bacteroidia.id.913	MR-PRESSO		0.059	0.52 (0.28, 0.97)
family.Alcaligenaceae.id.2875	Inverse variance weighted		0.011	0.50 (0.29, 0.86)
family.Alcaligenaceae.id.2875	Weighted median		0.026	0.43 (0.20, 0.90)
family.Alcaligenaceae.id.2875	Maximum likelihood		0.016	0.51 (0.29, 0.88)
family.Alcaligenaceae.id.2876	MR-PRESSO		0.020	0.50 (0.30, 0.85)
family.Veillonellaceae.id.2172	Inverse variance weighted		0.016	1.69 (1.10, 2.59)
family.Veillonellaceae.id.2172	Weighted median	-	- 0.059	1.80 (0.98, 3.30)
family.Veillonellaceae.id.2172	Maximum likelihood		0.016	1.72 (1.11, 2.66)
family.Veillonellaceae.id.2173	MR-PRESSO	_ 	0.026	1.69 (1.10, 2.59)
genus.Bilophila.id.3170	Inverse variance weighted		0.049	1.68 (1.00, 2.82)
genus.Bilophila.id.3170	Weighted median		0.502	1.27 (0.63, 2.59)
genus.Bilophila.id.3170	Maximum likelihood		0.044	1.72 (1.01, 2.91)
genus.Bilophila.id.3171	MR-PRESSO	· · · · · ·	0.069	1.68 (1.00, 2.82)
genus.Eggerthella.id.819	Inverse variance weighted		0.046	0.66 (0.44, 0.99)
genus.Eggerthella.id.819	Weighted median		0.026	0.55 (0.32, 0.93)
genus.Eggerthella.id.819	Maximum likelihood		0.043	0.67 (0.45, 0.99)
genus.Eggerthella.id.820	MR-PRESSO	-	0.074	0.66 (0.44, 0.99)
genus.LachnospiraceaeUCG004.id.11324	Inverse variance weighted		0.035	0.54 (0.31, 0.96)
genus.LachnospiraceaeUCG004.id.11324	Weighted median		0.152	0.57 (0.26, 1.23)
genus.LachnospiraceaeUCG004.id.11324	Maximum likelihood		0.037	0.54 (0.30, 0.96)
genus.LachnospiraceaeUCG004.id.11325	MR-PRESSO	-	0.016	0.54 (0.35, 0.83)
genus.LachnospiraceaeUCG010.id.11330	Inverse variance weighted		0.037	1.77 (1.03, 3.02)
genus.LachnospiraceaeUCG010.id.11330	Weighted median	1	0.118	1.77 (0.86, 3.63)
genus.LachnospiraceaeUCG010.id.11330	Maximum likelihood		- 0.036	1.79 (1.04, 3.10)
genus.LachnospiraceaeUCG010.id.11331	MR-PRESSO		0.045	1.77 (1.08, 2.90)
donus Parasuttoralla id 2802	Inverse variance weighted		0.035	0.64 (0.42, 0.07)
genus.Parasutterella.id.2892	Weighted median		0.035	0.59 (0.32, 1.06)
genus Parasutterella id 2802	Maximum likelihood		0.079	0.59 (0.52, 1.00)
genus Parasutterella id 2803	MR_PRESSO		0.040	0.64 (0.42, 0.98)
genus.r arasutterena.iu.2035	MICH NE000		0.000	0.04 (0.44, 0.32)
genus Sutterella id 2896	Inverse variance weighted		0.005	2 25 (1 27 3 99)
genus Sutterella id 2896	Weighted median		0.020	2.51 (1.16, 5.43)
genus Sutterella id 2896	Maximum likelihood		0.005	2.33 (1.29, 4.21)
genus Sutterella id 2897	MR-PRESSO		0.010	2.25 (1.34, 3.78)
9				
order.Bacillales.id.1674	Inverse variance weighted		0.002	1.60 (1.18, 2.16)
order.Bacillales.id.1674	Weighted median	<u> </u>	0.041	1.53 (1.02, 2.30)
order.Bacillales.id.1674	Maximum likelihood		0.003	1.61 (1.17, 2.20)
order.Bacillales.id.1675	MR-PRESSO		0.006	1.60 (1.23, 2.08)
				, , , , , , , , ,
order.Bacteroidales.id.913	Inverse variance weighted		0.040	0.52 (0.28, 0.97)
order.Bacteroidales.id.913	Weighted median		0.234	0.61 (0.27, 1.38)
order.Bacteroidales.id.913	Maximum likelihood	- -	0.031	0.53 (0.30, 0.95)
order.Bacteroidales.id.914	MR-PRESSO		0.059	0.52 (0.28, 0.97)
		0.5 1 2 3	4 5	

Negative association Positive association

553 Table 2

554 Causal associations of the gut microbiota with pancreatic cancer risk in the East Asian

555 population.

Exposure	Method		p value	OR(95%CI)
class.Actinobacteria.id.419	Inverse variance weighted		0.035	2.41 (1.06, 5.44)
class.Actinobacteria.id.419	Weighted median		0.517	1.42 (0.49, 4.09)
class.Actinobacteria.id.419	Maximum likelihood		0.015	2.51 (1.20, 5.28)
class.Actinobacteria.id.419	MR_PRESSO		0.058	2.41 (1.06, 5.44)
family.Christensenellaceae.id.1866	Inverse variance weighted	•	0.041	0.33 (0.11, 0.95)
family.Christensenellaceae.id.1866	Weighted median		0.061	0.27 (0.07, 1.07)
family.Christensenellaceae.id.1866	Maximum likelihood	- -	0.043	0.32 (0.11, 0.96)
family.Christensenellaceae.id.1866	MR_PRESSO	•-	0.024	0.33 (0.16, 0.68)
genusRuminococcusgnavusgroup.id.14376	Inverse variance weighted	-	0.020	0.50 (0.28, 0.90)
genusRuminococcusgnavusgroup.id.14376	Weighted median		0.206	0.62 (0.30, 1.30)
genusRuminococcusgnavusgroup.id.14376	Maximum likelihood		0.007	0.49 (0.29, 0.82)
genusRuminococcusgnavusgroup.id.14376	MR_PRESSO	+	0.042	0.50 (0.28, 0.90)
genus.Enterorhabdus.id.820	Inverse variance weighted	-	0.001	2.38 (1.40, 4.04)
genus.Enterorhabdus.id.820	Weighted median	·	0.036	2.10 (1.05, 4.20)
genus.Enterorhabdus.id.820	Maximum likelihood	-	0.002	2.43 (1.37, 4.30)
genus.Enterorhabdus.id.820	MR_PRESSO		0.005	2.38 (1.62, 3.51)
genus.Ruminococcus1.id.11373	Inverse variance weighted	-	0.023	0.35 (0.14, 0.87)
genus.Ruminococcus1.id.11373	Weighted median		0.062	0.31 (0.09, 1.06)
genus.Ruminococcus1.id.11373	Maximum likelihood	-	0.023	0.34 (0.13, 0.86)
genus.Ruminococcus1.id.11373	MR_PRESSO	•	0.025	0.35 (0.16, 0.75)
order.Burkholderiales.id.2874	Inverse variance weighted	•	0.024	0.37 (0.16, 0.88)
order.Burkholderiales.id.2874	Weighted median		0.369	0.58 (0.18, 1.91)
order.Burkholderiales.id.2874	Maximum likelihood		0.026	0.37 (0.15, 0.89)
order.Burkholderiales.id.2874	MR_PRESSO		0.041	0.37 (0.17, 0.84)
		0.5 1 2 3 4 5		

Negative association Positive association

577 Supplementary Figure 1

- 578 Scatter plot of the association between gut microbiota and pancreatic cancer based on UK
- 579 biobank database.
- 580 (A) class *Bacteroidia*; (B) family *Alcaligenaceae*; (C) family *Veillonellaceae*; (D) genus
- 581 Bilophila; (E) genus Eggerthella; (F) genus LachnospiraceaeUCG004; (G) genus

В

Н

Κ

- 582 *LachnospiraceaeUCG010;* (H) genus *Parasutterella;* (I) genus *Sutterella;* (J) order *Bacillales;*
- 583 (K) order *Bacteroidales*

















L



J

- 590 Supplementary Figure 2
- 591 Scatter plot of the association between gut microbiota and pancreatic cancer based on
- 592 Japan biobank database.
- 593 (A) class *Actinobacteria*; (B) family *Christensenellaceae*; (C) genus
- 594 Rumminococcusgnavusgroup; (D) genus Enterorhabdus; (E) genus Ruminococcus1; (F) ordr
- 595 Burkhoderiales



617 Supplementary Figure 3

- 618 Leave-one-out sensitivity analysis for the association between genetically predicted gut
- 619 microbiota and pancreatic cancer based on UK biobank database.
- 620 (A) class *Bacteroidia*; (B) family *Alcaligenaceae*; (C) family *Veillonellaceae*; (D) genus
- 621 Bilophila; (E) genus Eggerthella; (F) genus LachnospiraceaeUCG004; (G) genus
- 622 LachnospiraceaeUCG010; (H) genus Parasutterella; (I) genus Sutterella; (J) order Bacillales;
- 623 (K) order *Bacteroidales*



627 Supplementary Figure 4

- 628 Leave-one-out sensitivity analysis for the association between genetically predicted gut
- 629 microbiota and pancreatic cancer based on Japan biobank database.
- 630 (A) class *Actinobacteria*; (B) family *Christensenellaceae*; (C) genus
- 631 Rumminococcusgnavusgroup; (D) genus Enterorhabdus; (E) genus Ruminococcus1; (F) ordr

632 Burkhoderiales



633 634

635

636

637

638

639 640

6 10